<DOC>
	<DOCNO>NCT00908349</DOCNO>
	<brief_summary>Open-Label Extension Study Evaluate Long-Term Safety Tolerability Oxcarbazepine Extended-Release ( OXC XR )</brief_summary>
	<brief_title>Safety Tolerability OXC XR Adjunctive Therapy Subjects With Refractory Partial Epilepsy</brief_title>
	<detailed_description>NAP</detailed_description>
	<mesh_term>Epilepsy</mesh_term>
	<mesh_term>Epilepsies , Partial</mesh_term>
	<mesh_term>Oxcarbazepine</mesh_term>
	<mesh_term>Carbamazepine</mesh_term>
	<criteria>Inclusion Criteria 1 . Able provide write informed consent agree comply study procedure . 2 . Male female age 18 66 year , inclusive . 3 . Successful completion 804P301 study . 4 . Sexually active woman , unless surgically sterile ( least 6 month prior Study Medication [ SM ] administration ) least 1 year postmenopausal , must use effective method avoid pregnancy ( include oral , transdermal , implanted contraceptive [ hormonal method conjunction secondary method ] , intrauterine device , female condom spermicide , diaphragm spermicide , cervical cap , abstinence , use condom spermicide sexual partner sterile [ least 6 month prior SM administration ] sexual partner ) least four week prior SM administration , must agree continue use precaution End Study visit . Cessation birth control point discuss responsible physician . Exclusion Criteria 1 . Clinically significant change health status , opinion Investigator , would prevent subject participate study successfully complete study . 2 . Any reason , opinion Investigator , would prevent subject participate study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>66 Years</maximum_age>
	<verification_date>June 2012</verification_date>
</DOC>